Contact

All Stories

  1. Revised ISHAM-ABPA working group clinical practice guidelines for diagnosing, classifying and treating allergic bronchopulmonary aspergillosis/mycoses

    Article • European Respiratory Journal, February 2024, European Respiratory Society (ERS)

    Professor Richard B Moss

  2. Food and Drug Administration (FDA) Public Workshop Summary—Addressing Challenges in Inhaled Antifungal Drug Development

    Article • Clinical Infectious Diseases, October 2023, Oxford University Press (OUP)

    Professor Richard B Moss

  3. Correction: Moss, R.B. Severe Fungal Asthma: A Role for Biologics and Inhaled Antifungals. J. Fungi 2023, 9, 85

    Article • Journal of Fungi, April 2023, MDPI AG

    Professor Richard B Moss

  4. Evaluation of Acebilustat, a Selective Inhibitor of Leukotriene B4 Biosynthesis, for Treatment of Outpatients With Mild-Moderate Coronavirus Disease 2019: A Randomized, Double-Blind, Placebo-Controlled Phase 2 Trial

    Article • Clinical Infectious Diseases, March 2023, Oxford University Press (OUP)

    Professor Richard B Moss

  5. Severe Fungal Asthma: A Role for Biologics and Inhaled Antifungals

    Article • Journal of Fungi, January 2023, MDPI AG

    Professor Richard B Moss

  6. Rate of Lung Function Decline in People with Cystic Fibrosis Having a Residual Function Gene Mutation

    Article • Pulmonary Therapy, November 2022, Springer Science + Business Media

    Professor Richard B Moss

  7. Clinician variability in the diagnosis and treatment of aspergillus fumigatus-related conditions in cystic fibrosis: An international survey

    Article • Journal of Cystic Fibrosis, January 2022, Elsevier

    Professor Richard B Moss

  8. Biomarkers for the Diagnosis of Allergic Bronchopulmonary Aspergillosis in Cystic Fibrosis: A Systematic Review and Meta-Analysis

    Article • The Journal of Allergy and Clinical Immunology In Practice, May 2021, Elsevier

    Professor Richard B Moss

  9. Diagnosing allergic bronchopulmonary aspergillosis/mycosis: Return to lost horizons

    Article • Journal of Allergy and Clinical Immunology, April 2021, Elsevier

    Professor Richard B Moss

  10. Mucosal humoral immunity in cystic fibrosis - a tangled web of failed proteostasis, infection and adaptive immunity

    Article • EBioMedicine, October 2020, Elsevier

    Professor Richard B Moss

  11. Long-Term Ivacaftor in People Aged 6 Years and Older with Cystic Fibrosis with Ivacaftor-Responsive Mutations

    Article • Pulmonary Therapy, September 2020, Springer Science + Business Media

    Professor Richard B Moss

  12. Manifestations of pulmonary aspergillosis in pediatrics

    Article • Current Opinion in Pediatrics, June 2020, Wolters Kluwer Health

    Professor Richard B Moss

  13. Early Aspergillosis in Cystic Fibrosis and Air Trapping: Guilt by Association?

    Article • American Journal of Respiratory and Critical Care Medicine, March 2020, American Thoracic Society

    Professor Richard B Moss

  14. Mucus plugging, air trapping, and bronchiectasis are important outcome measures in assessing progressive childhood cystic fibrosis lung disease

    Article • Pediatric Pulmonology, January 2020, Wiley

    Professor Richard B Moss

  15. Resistin is elevated in cystic fibrosis sputum and correlates negatively with lung function

    Article • Journal of Cystic Fibrosis, January 2019, Elsevier

    Professor Richard B Moss

  16. Sweat rate analysis of ivacaftor potentiation of CFTR in non-CF adults

    Article • Scientific Reports, November 2018, Springer Science + Business Media

    Professor Richard B Moss

  17. The myriad challenges of respiratory fungal infection in cystic fibrosis

    Article • Pediatric Pulmonology, July 2018, Wiley

    Professor Richard B Moss

  18. Cystic fibrosis transmembrane conductance regulator modulators: precision medicine in cystic fibrosis

    Article • Current Opinion in Pediatrics, June 2018, Wolters Kluwer Health

    Professor Richard B Moss

  19. Susceptibility of Candida albicans from Cystic Fibrosis Patients

    Article • Mycopathologia, April 2017, Springer Science + Business Media

    Professor Richard B Moss

  20. The magnitude of ivacaftor effects on fluid secretion via R117H-CFTR channels: Human in vivo measurements

    Article • PLoS ONE, April 2017, PLOS

    Professor Richard B Moss

  21. Assessment of safety and efficacy of long-term treatment with combination lumacaftor and ivacaftor therapy in patients with cystic fibrosis homozygous for the F508del-CFTR mutation (PROGRESS): a phase 3, extension study

    Article • The Lancet Respiratory Medicine, February 2017, Elsevier

    Professor Richard B Moss

  22. Are Cystic Fibrosis Aspergillus fumigatus Isolates Different? Intermicrobial Interactions with Pseudomonas

    Article • Mycopathologia, November 2016, Springer Science + Business Media

    Professor Richard B Moss

  23. Basophil activation test determination of CD63 combined with CD203c is not superior to CD203c alone in identifying allergic bronchopulmonary aspergillosis in cystic fibrosis

    Article • Journal of Allergy and Clinical Immunology, October 2016, Elsevier

    Dr. Rabindra Tirouvanziam, Professor Richard B Moss

  24. Allergic Bronchopulmonary Aspergillosis

    Article • Journal of Fungi, June 2016, MDPI AG

    Professor Richard B Moss

  25. “Blood basophil activation is a reliable biomarker of allergic bronchopulmonary aspergillosis in cystic fibrosis.” Yael Gernez, Jeffrey Waters, Bojana Mirković, Gillian M. Lavelle, Colleen E. Dunn, Zoe A. Davies, Cassie Everson, Rabindra Tirouvanziam, ...

    Article • European Respiratory Journal, May 2016, European Respiratory Society (ERS)

    Dr. Rabindra Tirouvanziam, Professor Richard B Moss

  26. Effect of Media Modified To Mimic Cystic Fibrosis Sputum on the Susceptibility of Aspergillus fumigatus, and the Frequency of Resistance at One Center

    Article • Antimicrobial Agents and Chemotherapy, April 2016, ASM Journals

    Professor Richard B Moss

  27. Earth Mover’s Distance (EMD): A True Metric for Comparing Biomarker Expression Levels in Cell Populations

    Article • PLoS ONE, March 2016, PLOS

    Professor Richard B Moss

  28. Modulatory Effects of Aspergillus Colonization and Abpa on Blood and Sputum Granulocytes in CF

    Article • Journal of Allergy and Clinical Immunology, February 2016, Elsevier

    Dr. Rabindra Tirouvanziam, Professor Richard B Moss

  29. The basophil surface marker CD203c identifies Aspergillus species sensitization in patients with cystic fibrosis

    Article • Journal of Allergy and Clinical Immunology, February 2016, Elsevier

    Professor Richard B Moss

  30. Discusses advances in treating a common and serious complication of allergic asthma.

    Article • European Respiratory Journal, January 2016, European Respiratory Society (ERS)

    Professor Richard B Moss

  31. Blood basophil activation is a reliable biomarker of allergic bronchopulmonary aspergillosis in cystic fibrosis

    Article • European Respiratory Journal, November 2015, European Respiratory Society (ERS)

    Dr. Rabindra Tirouvanziam, Professor Richard B Moss

  32. Inhibition of Aspergillus fumigatus and Its Biofilm by Pseudomonas aeruginosa Is Dependent on the Source, Phenotype and Growth Conditions of the Bacterium

    Article • PLoS ONE, August 2015, PLOS

    Professor Richard B Moss

  33. Lumacaftor–Ivacaftor in Patients with Cystic Fibrosis Homozygous for Phe508delCFTR

    Article • New England Journal of Medicine, July 2015, New England Journal of Medicine (NEJM/MMS)

    Professor Richard B Moss

  34. Efficacy and safety of ivacaftor in patients with cystic fibrosis who have an Arg117His-CFTR mutation: a double-blind, randomised controlled trial

    Article • The Lancet Respiratory Medicine, July 2015, Elsevier

    Professor Richard B Moss

  35. Molecular epidemiology of Aspergillus collected from cystic fibrosis patients

    Article • Journal of Cystic Fibrosis, July 2015, Elsevier

    Professor Richard B Moss

  36. Recent advances in cystic fibrosis

    Article • Current Opinion in Pediatrics, June 2015, Wolters Kluwer Health

    Professor Richard B Moss

  37. Fungi in Cystic Fibrosis and Non–Cystic Fibrosis Bronchiectasis

    Article • Seminars in Respiratory and Critical Care Medicine, March 2015, Thieme Publishing Group

    Professor Richard B Moss

  38. Long-term treatment with oral N-acetylcysteine: Affects lung function but not sputum inflammation in cystic fibrosis subjects. A phase II randomized placebo-controlled trial

    Article • Journal of Cystic Fibrosis, March 2015, Elsevier

    Professor Richard B Moss

  39. A CFTR corrector (lumacaftor) and a CFTR potentiator (ivacaftor) for treatment of patients with cystic fibrosis who have a phe508del CFTR mutation: a phase 2 randomised controlled trial

    Article • The Lancet Respiratory Medicine, July 2014, Elsevier

    Professor Richard B Moss

  40. Ataluren for the treatment of nonsense-mutation cystic fibrosis: a randomised, double-blind, placebo-controlled phase 3 trial

    Article • The Lancet Respiratory Medicine, July 2014, Elsevier

    Professor Richard B Moss

  41. A Little CFTR Goes a Long Way: CFTR-Dependent Sweat Secretion from G551D and R117H-5T Cystic Fibrosis Subjects Taking Ivacaftor

    Article • PLoS ONE, February 2014, PLOS

    Professor Il-Ho Park, Professor Richard B Moss

  42. Basophil Activation Is a Reliable Biomarker Of Allergic Bronchopulmonary Aspergillosis (ABPA) In CF: One Year Results Of a Longitudinal Cohort Study

    Article • Journal of Allergy and Clinical Immunology, February 2014, Elsevier

    Dr. Rabindra Tirouvanziam, Professor Richard B Moss

  43. Treatment options in severe fungal asthma and allergic bronchopulmonary aspergillosis

    Article • European Respiratory Journal, December 2013, European Respiratory Society (ERS)

    Professor Richard B Moss

  44. Allergic bronchopulmonary aspergillosis: review of literature and proposal of new diagnostic and classification criteria

    Article • Clinical & Experimental Allergy, July 2013, Wiley

    Dr Jacques F Meis, Professor Richard B Moss

  45. Optimizing Nasal Potential Difference Analysis for CFTR Modulator Development: Assessment of Ivacaftor in CF Subjects with the G551D-CFTR Mutation

    Article • PLoS ONE, July 2013, PLOS

    Professor Richard B Moss

  46. Safety and early treatment effects of the CXCR2 antagonist SB-656933 in patients with cystic fibrosis

    Article • Journal of Cystic Fibrosis, May 2013, Elsevier

    Professor Richard B Moss

  47. Pitfalls of Drug Development: Lessons Learned from Trials of Denufosol in Cystic Fibrosis

    Article • The Journal of Pediatrics, April 2013, Elsevier

    Professor Richard B Moss

  48. Sputum Tobramycin Concentrations in Cystic Fibrosis Patients with Repeated Administration of Inhaled Tobramycin

    Article • Journal of Aerosol Medicine and Pulmonary Drug Delivery, April 2013, Mary Ann Liebert Inc

    Professor Richard B Moss

  49. Current treatment options for invasive aspergillosis

    Article • Drugs of Today, January 2013, Portico

    Professor Richard B Moss

  50. Blood basophils from cystic fibrosis patients with allergic bronchopulmonary aspergillosis are primed and hyper-responsive to stimulation by aspergillus allergens

    Article • Journal of Cystic Fibrosis, December 2012, Elsevier

    Dr. Rabindra Tirouvanziam, Professor Richard B Moss

  51. Long term effects of denufosol tetrasodium in patients with cystic fibrosis

    Article • Journal of Cystic Fibrosis, December 2012, Elsevier

    Professor Richard B Moss

  52. Fungi and allergic lower respiratory tract diseases

    Article • Journal of Allergy and Clinical Immunology, February 2012, Elsevier

    Professor Richard B Moss

  53. Specific Induction Of CD203c Expression In Blood Basophils Discriminates Between CF patients With Aspergillus Colonization And Those With CF-ABPA

    Article • Journal of Allergy and Clinical Immunology, February 2012, Elsevier

    Professor Richard B Moss

  54. Socioeconomic Status and the Likelihood of Antibiotic Treatment for Signs and Symptoms of Pulmonary Exacerbation in Children with Cystic Fibrosis

    Article • The Journal of Pediatrics, November 2011, Elsevier

    Professor Richard B Moss

  55. Results of a phase IIa study of VX-809, an investigational CFTR corrector compound, in subjects with cystic fibrosis homozygous for theF508del-CFTRmutation

    Article • Thorax, August 2011, BMJ

    Professor Richard B Moss

  56. Denufosol Tetrasodium in Patients with Cystic Fibrosis and Normal to Mildly Impaired Lung Function

    Article • American Journal of Respiratory and Critical Care Medicine, March 2011, American Thoracic Society

    Theodore Liou, Professor Richard B Moss

  57. Allergic bronchopulmonary aspergillosis and Aspergillus infection in cystic fibrosis

    Article • Current Opinion in Pulmonary Medicine, November 2010, Wolters Kluwer Health

    Professor Richard B Moss

  58. Baseline Characteristics and Factors Associated With Nutritional and Pulmonary Status at Enrollment in the Cystic Fibrosis EPIC Observational Cohort

    Article • Pediatric Pulmonology, July 2010, Wiley

    Professor Richard B Moss

  59. Safety, Tolerability, and Efficacy of High-Frequency Chest Wall Oscillation in Pediatric Patients With Cerebral Palsy and Neuromuscular Diseases: An Exploratory Randomized Controlled Trial

    Article • Journal of Child Neurology, March 2010, SAGE Publications

    Professor Richard B Moss

  60. Cystic fibrosis HRCT scores correlate strongly with pseudomonas infection

    Article • Pediatric Pulmonology, October 2009, Wiley

    Professor Richard B Moss

  61. Study Of Sublingual Immunotherapy In Subjects With Dermatophagoides Farniae And Timothy Grass Allergy

    Article • Journal of Allergy and Clinical Immunology, February 2009, Elsevier

    Professor Richard B Moss

  62. Highlights of a workshop to discuss targeting inflammation in cystic fibrosis

    Article • Journal of Cystic Fibrosis, January 2009, Elsevier

    Professor Richard B Moss

  63. No Detectable Improvements in Cystic Fibrosis Transmembrane Conductance Regulator by Nasal Aminoglycosides in Patients with Cystic Fibrosis with Stop Mutations

    Article • American Journal of Respiratory Cell and Molecular Biology, July 2007, American Thoracic Society

    Dr Robert A Oster, Professor Richard B Moss

  64. Duration of treatment effect after tobramycin solution for inhalation in young children with cystic fibrosis

    Article • Pediatric Pulmonology, May 2007, Wiley

    Professor Richard B Moss

  65. Critique of trials in allergic bronchopulmonary aspergillosis and fungal allergy

    Article • Medical Mycology, September 2006, Oxford University Press (OUP)

    Professor Richard B Moss

  66. High-dose oral N -acetylcysteine, a glutathione prodrug, modulates inflammation in cystic fibrosis

    Article • Proceedings of the National Academy of Sciences, March 2006, Proceedings of the National Academy of Sciences

    Professor Richard B Moss

  67. Pathophysiology and immunology of allergic bronchopulmonary aspergillosis

    Article • Medical Mycology, January 2005, Oxford University Press (OUP)

    Professor Richard B Moss

  68. Novel contributions to the Asian CFTR mutation spectrum: Genotype and phenotype in Thai patients with cystic fibrosis

    Article • American Journal of Medical Genetics Part A, January 2005, Wiley

    Professor Richard B Moss

  69. Quantitative air‐trapping analysis in children with mild cystic fibrosis lung disease

    Article • Pediatric Pulmonology, September 2004, Wiley

    Professor Richard B Moss

  70. Composite Spirometric–Computed Tomography Outcome Measure in Early Cystic Fibrosis Lung Disease

    Article • American Journal of Respiratory and Critical Care Medicine, September 2003, American Thoracic Society

    Professor Richard B Moss

  71. Significant Microbiological Effect of Inhaled Tobramycin in Young Children with Cystic Fibrosis

    Article • American Journal of Respiratory and Critical Care Medicine, March 2003, American Thoracic Society

    Professor Richard B Moss

  72. Allergic Bronchopulmonary Aspergillosis

    Article • CHEST Journal, July 2000, Elsevier

    Professor Richard B Moss

  73. Defective function of the cystic fibrosis-causing missense mutation G551D is recovered by genistein

    Article • AJP Cell Physiology, October 1999, American Physiological Society

    Professor Richard B Moss

  74. Spirometer-Triggered High Resolution Computed Tomography (HRCT) of the Chest, Clinical Score, and Pulmonary Function Measurements in Cystic Fibrosis (CF) Patients before and after Treatment for a Pulmonary Exacerbation

    Article • Pediatric Research, April 1999, Springer Science + Business Media

    Professor Richard B Moss

  75. Vocal Cord Dysfunction Syndrome and “Steroid-Dependent” Asthmatics

    Article • CHEST Journal, December 1995, Elsevier

    Professor Richard B Moss

  76. 486 Defective antibody-mediated opsonization of pseudomonas aeruginosa (PA) in cystic fibrosis (CF): An isotype-dependent deffect?

    Article • Journal of Allergy and Clinical Immunology, January 1988, Elsevier

    Professor Richard B Moss

  77. 493 Suppression of the Late Cutaneous Response (LCR) by immunotherapy (IT)

    Article • Journal of Allergy and Clinical Immunology, January 1988, Elsevier

    Professor Richard B Moss

  78. 282 A quantitative immunoenzymatic assay for grass pollen-specific IgG antibodies

    Article • Journal of Allergy and Clinical Immunology, January 1985, Elsevier

    Professor Richard B Moss

  79. 8 Once a day theophylline (uniphyl) for treatment of patients with asthma (AS) and cystic fibrosis(CF)

    Article • Journal of Allergy and Clinical Immunology, January 1985, Elsevier

    Professor Richard B Moss

  80. 124 Grass pollen immunotherapy, clinical and immunologic effects in a double-blind placebo-controlled study

    Article • Journal of Allergy and Clinical Immunology, January 1983, Elsevier

    Professor Richard B Moss

  81. 37 Infantile allergy and milk-specific antibodies in breast milk

    Article • Journal of Allergy and Clinical Immunology, January 1983, Elsevier

    Professor Richard B Moss